Tech Company Financing Transactions
Alector Funding Round
AbbVie Biotech Ventures, Amgen Ventures and Casdin Capital invested in a $133 million Series E venture round for Alector. The round was announced on 7/26/2018.
Transaction Overview
Company Name
Announced On
7/26/2018
Transaction Type
Venture Equity
Amount
$133,000,000
Round
Series E
Investors
Proceeds Purpose
The proceeds from the financing will be used to advance Alector's clinical programs and expand the company's discovery platform.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
131 Oyster Point Blvd. 600
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Alector (Nasdaq: ALEC) is combining state-of-the-art antibody technology and recent discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer's disease, other forms of dementia, and mechanistically related neurodegenerative disorders.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 7/26/2018: MedAvail venture capital transaction
Next: 7/26/2018: Cazena venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs